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ABSTRACT
Objectives: Clinical trials provide ‘gold standard’
evidence for policy, but insufficient locally relevant
trials are conducted in low-income and middle-income
countries. Local investigator-initiated trials could
generate highly relevant data for national governments,
but information is lacking on how to facilitate them.
We aimed to identify barriers and enablers to
investigator-initiated trials in Ethiopia to inform and
direct capacity strengthening initiatives.
Design: Exploratory, qualitative study comprising of
in-depth interviews (n=7) and focus group discussions
(n=3).
Setting: Fieldwork took place in Ethiopia during March
2011.
Participants: Local health researchers with previous
experiences of clinical trials or stakeholders with an
interest in trials were recruited through snowball
sampling (n=20).
Outcome measures: Detailed discussion notes were
analysed using thematic coding analysis and key
themes were identified.
Results: All participants perceived investigator-
initiated trials as important for generating local
evidence. System and organisational barriers included:
limited funding allocation, weak regulatory and
administrative systems, few learning opportunities,
limited human and material capacity and poor
incentives for conducting research. Operational hurdles
were symptomatic of these barriers. Lack of awareness,
confidence and motivation to undertake trials were
important individual barriers. Training, knowledge
sharing and experience exchange were key enablers to
trial conduct and collaboration was unanimously
regarded as important for improving capacity.
Conclusions: Barriers to trial conduct were found at
individual, operational, organisational and system
levels. These findings indicate that to increase locally
led trial conduct in Ethiopia, system wide changes are
needed to create a more receptive and enabling
research environment. Crucially, the creation of
research networks between potential trial groups could
provide much needed practical collaborative support
through sharing of financial and project management
burdens, knowledge and resources. These findings
could have important implications for
capacity-strengthening initiatives but further research is
needed before the results can be generalised more
widely.
INTRODUCTION
Many development organisations argue that
clinical research in low and middle income
countries (LMIC) is essential for improving
public health and development.1 In LMICs
clinical research capacity remains insufﬁ-
cient. This perpetuates the ‘10/90 gap’,
where only 10% of global health research
expenditure is allocated to diseases that pri-
marily affect 90% of the world’s population.
This leads to a lack of evidence of the
world’s most burdensome diseases.2
Evidence from Northern nations is often not
relevant to LMICs,3 and its adoption into
Strengths and limitations of this study
▪ To our knowledge this is the first empirical
research study exploring investigator-initiated
trial implementation in low-income and
middle-income countries.
▪ Gives a compelling voice to local investigators
who are often unheard in this Northern domi-
nated discourse.
▪ As a formative study, the sample size was small,
the sampling purposive and the findings may be
context specific.
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clinical practice can be slow and treated with caution.1 4
Increasing the number of clinical trials conducted in
LMICs would help generate local evidence,4 which may
be more likely to rapidly inﬂuence policy and practice.5
Most clinical trials conducted in LMICs are run by
foreign research organisations with their own agendas.
Recently there have been calls from within LMICs for
more ownership over priority setting,6 greater engage-
ment with local research communities7 and research
conducted in line with national health strategies.8
Pragmatic, locally initiated disease management studies
could signiﬁcantly improve public health.4 Despite being
simple and cost-effective, they are often ignored by inter-
national trial groups,9 and are rarely independently
undertaken in LMICs. By ‘pragmatic’ and ‘simple’ we
are referring to studies that are designed to test effective-
ness, have few endpoints and broad eligibility criteria,
thereby increasing external validity.10 11 Meanwhile,
there is increasing expectation that LMICs should take
more responsibility for their research activities.12
Increasing the number of local investigator-initiated
trials (IITs) could be an answer to these issues. Several
advantages of IITs over foreign-initiated trials (FITs)
have been put forward (box 1).
The establishment of African-owned research centres
capable of running their own clinical trials has been
identiﬁed as an international priority,17 and there are
ever increasing numbers of clinical trials being con-
ducted in LMICs.4 However, few of these trials are
locally initiated,18 and globally, trials are becoming
harder to implement.4 Many research bodies have
increased efforts to support IITs in Europe,18 19 but
within LMICs capacity building mostly focuses on devel-
oping sites to run international trials. Capacity building
to support independent locally led trials is likely to
require a different approach. However, little is known
about the best way to develop capacity and facilitate
their conduct. This formative study investigates the
issues facing local trial investigators in Ethiopia, and was
designed to begin addressing this knowledge gap by
determining the barriers and enablers to trial conduct.
METHODS
We conducted a qualitative study using in-depth inter-
views (IDIs) and focus group discussions (FGDs).
Research exercises took place in Addis Ababa and
Gondar, Ethiopia, in March and April 2011. Ethiopia
was selected to represent a country in Sub-Saharan
Africa that conducts a modest number of clinical trials
while having sufﬁcient trial experience to contribute to
this study. Ethiopia had 39 trials registered at the time of
ﬁeldwork; a breakdown of these by intervention and
sponsor is shown in ﬁgure 1. The majority of drug trials
investigated the use of approved drugs to optimise
treatment.
This study seeks to understand the perspectives and
experiences of current and potential trial investigators
and staff. Owing to the paucity of previous work on this
topic, we did not prospectively adopt a speciﬁc theoret-
ical framework. However, research questions were inﬂu-
enced by the ﬁelds of organisational change and
development. FGDs and IDIs were semistructured and
explored the following themes: the clinical research
environment in Ethiopia, barriers and enablers to trial
conduct, access to appropriate skills and knowledge,
current support for clinical trials and recommendations
for change. Questions were tailored to participant
experience and emerging themes.
Participants were identiﬁed ﬁrst through trial registra-
tion searches and subsequently by snowball sampling
from these individuals. Health researchers with previous
experiences of clinical trials or stakeholders with an
interest in trials were selected. Of all the participants
approached, none refused to take part. Interviews and
discussions were conducted in English, and explored key
points until no new information emerged. In prelimin-
ary meetings, participants said they would speak more
openly if discussions were not audio recorded. This was
because they would be uncomfortable criticising part-
ners or regulatory bodies while being recorded. One
participant explained that this worry was a result of the
legacy left by previous authoritarian regimes. Detailed
notes were taken with quotes noted as near verbatim as
possible, detailing identiﬁcation numbers.
This study was approved by the University of Oxford
Tropical Research Ethics Committee. Verbal informed
consent was obtained from all participants and review of
discussion contributions and written conﬁrmatory per-
mission was obtained for all participants who could be
contacted (15/20). No quotes are included from those
who could not be contacted.
Notes were analysed by thematic coding analysis using
Nvivo qualitative data analysis package (QSR
International Pty Ltd. V.9, 2011) to help organise the
data. Data were coded inductively according to its
semantic content.20 Using relationship and modelling
functions, a mechanistic model of factors inﬂuential to
clinical trial conduct was developed through the piecing
together of complementary segments of data contribu-
ted from different participants. Coding was completed
Box 1 Advantages of investigator-initiated trials over
foreign-initiated trials
▸ More applicable to local populations due to building on local
healthcare knowledge13
▸ More demand-led and responsive to a country’s needs
because they are driven by a national agenda9
▸ More likely to influence policy13 and sustainably link research
to action14
▸ Often simple studies that address important topics such as
disease management4 9
▸ Involve local staff at all levels and stages of trial conduct,15 so
there is more opportunity for ‘learning by doing’ and skill
development16
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by SF with consultation and agreement from other
authors (TL, CC and BA). Findings were reviewed and
commented on by all authors.
RESULTS
Study population
We conducted two FGDs and six interviews in Addis
Ababa and one FGD and one interview in Gondar. A
total of 20 researchers participated; seven were based at
a research centre, one at an NGO, eight at a hospital
and four at a university. Participants had varied job
roles. Those currently working on a clinical trial
included: senior investigators (n=2), trial managers and
coordinators (n=5), laboratory personnel (n=5) and
research nurses (n=2). We also recruited six medical
researchers not currently working on a clinical trial,
three of whom had previous trial experience and three
that did not. The participants had experience in a
diverse range of medical professional experience
domains (ﬁgure 2).
A role for investigator-initiated trials
All participants reported that too few clinical trials are
conducted in Ethiopia, and felt this limited the ability
for guidelines to be based on local evidence. Most treat-
ment strategies were based on international guidelines,
which many participants thought could be inappropri-
ate. Participants proposed that locally-led trials would be
useful for ﬁlling this evidence gap and that the conduct
of simple design studies was independently achievable.
Many researchers would like to lead their own studies
and had important questions, but were often unsure of
how to go about doing this, as described by this senior
clinician:
We don’t have the evidence to change local practices but
we deﬁnitely know some written guidelines don’t work.
There are a number of unanswered questions for trials
but we don’t know how to do them. We need clinical
research [in disease areas] that has a different effect in
Ethiopia, for example HIV and TB. These diseases are
similar as to other places but we have had little success
[controlling them] here. So why? Where are the mis-
takes? These sorts of investigations are easy, they would
support awareness and ﬁll gaps. FGD—3 PPT—1
Compared to foreign-led studies, local trials were per-
ceived to be more likely to address evidence gaps, be
more useful for developing treatment guidelines and
more sensitive to community issues. One junior clinician
described this through his experiences:
Investigator-initiated trials increase evidence, particularly
locally relevant evidence. For instance the Leishmania
Figure 1 Number of clinical
trials in Ethiopia by intervention
type and sponsor, as registered
on the WHO International Clinical
Trials Registry Platform in the
same period as data collection
(30 April 2011). The observational
study was registered as a clinical
trial but was a cohort study with a
nested cross-sectional design.
Figure 2 Participant experience of different medical
professional experience domains. Experience domains are
not mutually exclusive and one participant can have multiple
experience domains.
Franzen SRP, Chandler C, Enquselassie F, et al. BMJ Open 2013;3:e003616. doi:10.1136/bmjopen-2013-003616 3
Open Access
strain in Gondar seems to be a bit different to the other
strains because the drug treatment is working better in
the other areas. This will prevent mistakes in clinical
care. INT—6 PPT—1
Human and material capacity
While a general lack of materials, infrastructure and
laboratory facilities were thought to reduce the number
and scope of trials, most participants felt that human
resources were the critical factor. Respondents stated
that there were too few investigators with the technical
expertise to initiate a trial. There was also a shortage of
skilled research staff, with one investigator stating that if
one or two staff left, their trial could not continue (FGD
—3 PPT—1 senior clinician and trial investigator). This
lack of expertise and research skills was blamed on
minimal research focus in clinical education, few oppor-
tunities to gain experience and few local experts who
could share their knowledge.
From my undergraduate experience, I was trained to be
a clinician and not a researcher; this is from a curriculum
point of view. Few clinicians use clinical trials as they are
involved in primary care and not research. They have no
spare time to think about research…We need the oppor-
tunity to have a simple role and experience to get more
people to do more trials. As more people get involved in
simple research and trials, more research will be done.
INT—6 PPT—1, trial clinician
Individuals skilled in trials were often too busy with
regular duties to be able to conduct research. Most
senior trial staff were clinicians and while release from
routine duties could be negotiated, they complained
that healthcare tasks still had to be prioritised.
Academics had allocated time for research but this was
regularly cited as insufﬁcient. The limited manpower
allocation to research and few opportunities to gain
experience resulted in a negative feedback loop, as
explained by this trial clinician:
The scope of activities is narrowed by the time and eco-
nomic constraints and the fact few individuals can be
involved. Because the scope is narrowed this results in a
cycle of fewer people being involved, which in turn
results in less motivation, fewer trials and less exposure
and realising the way of thinking and less achievement.
Then less people are involved and there are fewer trials.
INT—6 PPT—1
Regulatory and other administrative bottlenecks
Respondents reported that complex and strict govern-
ment regulations made it very difﬁcult to investigate
novel interventions and recruit vulnerable populations.
Regulatory and ethical review times also introduced
delays and it was not uncommon for grants to expire
before all approvals were in place. A trial principal inves-
tigator (PI) explains this further:
Regulatory authorities have no clear guidelines so it is
problematic getting approvals. They are also not experi-
enced enough and so are overcautious and they cannot
decide on interpretations. FGD-1 PPT-1, Trial PI
Ethics committee members admitted that limited
resources, knowledge gaps and membership shortages
slowed review times, but also pointed out that poor
quality applications meant resubmission was regularly
required. They emphasised that clariﬁcation of regula-
tions and developing review capacity were essential to
facilitate trial implementation and that more training in
research ethics was needed. One participant explained
that The Ethiopian Bioethics Initiative is already
working towards this. Funded by the European and
Developing Countries Clinical Trial Partnership, The
Ethiopian Bioethics Initiative helps research sites to
form Institutional Review Boards (IRBs) and train the
committee members on basic principles of ethical clear-
ance. Under this grant they have established and trained
11 IRBs.
University and government administration systems
were unanimously regarded as overly complicated and
blamed for many operational delays. To cope with this,
many investigators said they required an administrative
assistant but could not afford one.
The university ﬁnance department is a bottleneck. You
really need an admin assistant to help with this. Most
doctors do not want to go through the pain of organising
and administrating all this. Also if you do not report your
annual budget on time you may be penalised and have
your salary suspended. The clinical trial ﬁnancing really
increases the amount of work you must do for your
budget reporting. If I got a good grant I would hire an
admin or research student to manage these issues. INT—
3 PPT-1, clinician
Operational hurdles
During one in-depth interview, a process mapping exer-
cise was used as a template for discussion; the partici-
pant draws a detailed ﬂow diagram of the steps and tasks
involved in conducting their clinical trial, noting pro-
blems, successes and changes to be made in hindsight.
Box 2 describes the experience of one PI, providing an
example case of operational hurdles and the importance
of advanced planning.
The majority of serious operational difﬁculties
occurred during the start-up stage of trial conduct.
Once intervention delivery began, there were few major
challenges. Participants attributed most operational
hurdles to wider issues. The main operational hurdles
and their causes are summarised in table 1. Operational
enablers included: keeping trial designs simple, only
investigating approved interventions and non-vulnerable
populations to prevent regulatory delays, and rapid
recruitment of participants due to large patient pools
that were usually prepared to give consent.
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Initiating an idea: awareness, confidence and motivation
Participants reported that limited awareness of trial
research among their colleagues was a common reason
for trials not being attempted. This was because potential
investigators were not exposed to the methodology or
had not considered doing them, as explained by this PI:
People do not have the vision that clinical trials will
improve patient care because they do not see it in their
daily lives. Clinical trials are important but essentially
people do not see them enough to think of them.
INT—4 PPT-1, senior clinician
This was attributed to omissions in medical student
curricula, limited access to literature, little trial research
training and few trial opportunities. If individuals had
considered conducting a trial, many participants said
that most researchers were not conﬁdent to initiate one
themselves because they lacked the knowledge and
skills. Even investigators who had considerable experi-
ence on foreign-led studies said they did not feel ready
to lead their own. The expectation of operational difﬁ-
culties and few examples of role models successfully con-
ducting trials created a ‘phobia’ of trial research, with
people believing them to be almost impossible. This
‘phobia’ and lack of awareness was seen as a key barrier
to trial conduct, as explained by this junior trial
investigator:
We need to develop and support a research culture by
capacity building to develop skills and resources, not big
capacity building like an operating room, but small scale
like small grants for beginner researchers to do research
and get practice—this would take away the phobia of
writing proposals and publications. When the phobia has
gone there will be ﬂoods of research. We need to open
our eyes and see what can be done. For instance people
don’t know how to write a proposal. In people’s academic
studies this sort of stuff is not given priority. Even small
research will be an eye opener and the phobia will be
gone. FGD—3 PPT—2, clinician and junior investigator
Even when potential investigators felt ready to
conduct a trial, many participants said that the motiv-
ation for undertaking them was insufﬁcient and this dis-
couraged their colleagues from attempting them.
Participants were encouraged by altruistic incentives
such as community health improvement and organisa-
tional development but personal career incentives were
weak. A lack of research career options discouraged stu-
dents from entering into research after studies or caused
them to migrate for work, as this junior academic
explained:
We need to make sure people get jobs and an established
career in research to get them to stay in their home
country or to come back to their home country after
training or education abroad. INT—2 PPT-1
Researchers also reported little recognition for
research and that promotion could be achieved without
doing research. Additionally, strong salary and workload
disincentives were cited, as summarised by this IDI
participant:
Box 2 Experience of a local principal investigator (PI) on
a foreign non-government organisation-led non-commercial
study
Registering the clinical trial caused considerable delays because
task allocation was overlooked. Ethical approval for this relatively
complex study took 12 months due to a cycle of resubmission.
Ordering to delivery of supplies routinely took 3–6 months. Data
entry and analysis were delayed because the data management
system had not been considered early enough and training could
only be obtained in Europe. Some laboratory tests were out-
sourced to a local private laboratory because staff lacked the train-
ing and equipment, while other assays were complicated by lack
of normal ranges for local populations. In hindsight the PI would
have taken more care with planning and preparation and made
roles and responsibilities clear from the outset.
Table 1 Participant reported operational hurdles and their
causes
Operational hurdles Reported causes
1. Difficulty writing
proposals and gaining
funding
▸ Little local funding,
competitive international
funding
▸ Technical ability and
confidence lacking
▸ Unsure of funding
process; investigators do
not complete application
▸ Lack of training
2. Slow regulatory and
ethical approvals
▸ Complex and unclear
guidelines
▸ Limited ethical review
capacity
▸ Poor-quality submissions
3. Problems with trial
management
▸ Lack of experience and
poor planning
4. Burdensome
administration and
difficulty purchasing
supplies
▸ Complex and slow
systems
▸ No administrative support
5. Problems with setting
up and running
laboratory tests
▸ Limited funds and facilities
▸ Difficulty purchasing
supplies
▸ Lack knowledge in
technologically advanced
procedures
Franzen SRP, Chandler C, Enquselassie F, et al. BMJ Open 2013;3:e003616. doi:10.1136/bmjopen-2013-003616 5
Open Access
The problem is that this [clinical trial research] will take
lots of your time and while it is possible to reduce your
clinic hours, this means you would lose money. The
country does not pay you even though it is for public
beneﬁt. There is no incentive, in short”. INT—4 PPT -1,
senior clinician
The key enablers: training, knowledge sharing and
experience exchange
Equal to their value for building technical competence,
many participants saw trial training, knowledge sharing
and experience exchange as key enablers for increasing
awareness, conﬁdence and motivation. Training was
viewed as important for awareness and encouraging staff
to consider their workplace challenges in a more enquir-
ing light. Knowledge sharing boosted a researcher’s con-
ﬁdence that trials were achievable and experience
exchange was important for raising professional stan-
dards and dispelling what one respondent termed
‘pseudo-conﬁdence’ (INT—4 PPT-1—Clinician and trial
PI); meaning to continue working in a suboptimum way
because knowledge of more rigorous methods was
lacking. Many participants emphasised that all these
enablers would be more effective if grounded in local
examples and context, such as knowledge sharing with
individuals whose settings were similar to the research-
er’s own. Learning activities were also highly motiv-
ational because they were prized for both personal and
professional development. Given the scarcity of trial
opportunities in Ethiopia, some participants suggested
that national or international experience exchange pro-
grammes would be useful. One FGD participant
explained her trial team’s experiences:
What we really want is for a south-south collaboration like
Kenya or Uganda to do exchange placements for our
junior staff. This would show people in resource-limited
settings it is possible to do trials and would motivate
people much more than website or e-learning…She
[referring to research nurse] has been to Kenya and
Switzerland and this has helped her to see how clinical
trials are done and what is good and bad and see the pos-
sibilities. FGD—3 PPT-1, senior clinician and trial
investigator
The importance of collaboration
While some respondents had negative experiences with
foreign led-studies or said they would prefer to be less
dependent on foreign groups, most participants were
very positive about international collaborations, assum-
ing intellectual independence could be protected.
Technical expertise and infrastructure strengthening
provided through collaborations were consistently pro-
posed as a solution to the limited human and material
resources. Particularly, collaborative grant applications
had been very helpful for securing funding by increas-
ing the quality and credibility of applications. Local and
international collaboration was also seen as a key way to
access and promote training, knowledge sharing and
experience exchange. This senior academic summarises
the general opinion:
The priority is addressing local concerns like ﬁeld–based
optimisation. Weight should be given to locally initiated
ideas. However, you should then ask for international
assistance and collaboration. The investigator-initiated
trial is all about the idea and not about the operation.
You do not have to re-invent the wheel; you should make
the most of global knowledge and skills. Everyone should
chip in with their appropriate competence and expertise.
This way the work will be faster and more efﬁcient and
local researchers will have access to technologies. INT—1
PPT-1
However, junior participants said they lacked the con-
tacts and knowledge to develop partnerships and even
established researchers often felt intellectually isolated
from the East African and wider research community.
This was believed to hamper innovation and cause repe-
tition of ideas.
DISCUSSION
This study highlights that Ethiopian investigators think
that investigator-initiated trials would generate highly
useful and applicable data, supporting the call for more
local evidence generation in LMICs. The challenge is
implementing and successfully conducting a locally led
study. We have identiﬁed barriers to the implementation
of investigator-initiated trials in Ethiopia at all levels of
the research system. Exploring through the perspective
of local investigators has given a critical understanding
of how these issues inﬂuence their ability to initiate
trials. We have demonstrated the importance of training,
knowledge sharing, experience exchange and collabor-
ation, for breaking down barriers in somewhat unex-
pected ways and now consider, in light of this, how
locally-led trials can be better supported.
The research system
Health research systems represent the coordinated activ-
ities of all stakeholders to produce health research and
may operate at local, national, regional or global levels.
The four main functions of health research systems are:
stewardship, ﬁnancing, resources and producing and
using research.21 In Ethiopia, barriers and enablers to
trial conduct have been identiﬁed at all levels of the
national research system; system, organisational and indi-
vidual. The main inﬂuential factors identiﬁed in this
study have been summarised into a mechanistic model
(ﬁgure 3). The following description is intended to illus-
trate the interconnected nature of the barriers to trial
research and how deﬁciencies at one level can have cas-
cading negative effects. System level barriers impact on
all levels through often dysfunctional regulatory and
administrative systems, insufﬁcient funding allocation
and limited ethical review capacity. Suffering from
limited resources, the organisational level provides
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limited learning opportunities, which negatively impacts
on human resources. These deﬁciencies, combined with
adverse regulatory and administrative systems, make
operating clinical trials difﬁcult. The combined effects
of insufﬁcient resources, limited learning opportunities
and difﬁcult operations result in a disabling research
environment at an individual level. This reduces aware-
ness of trials, limits competence and conﬁdence and
reduces motivation to undertake them. Few trials are
attempted and this forms a negative feedback loop by
reducing opportunities for experience.
A detailed review of the Ethiopian Health Research
System also cites slow regulatory and ethical review, difﬁ-
cult administration systems, limited human resource allo-
cation and few incentives as major impediments.22
However, it is important to emphasise that our descrip-
tion is not universal and individual examples of enabling
practices and trial capacity exist. Furthermore, no infor-
mation was available to us on the number of trial appli-
cations, rejections and turnaround times and although
little local evidence-based practice was reported, this was
not conﬁrmed by the authorities and examples of local
trials inﬂuencing policy are found in the literature.23
Nevertheless these results demonstrate the importance
of taking a system-wide view to research development.
Operational problems are embedded in wider issues,
and while certain strategies may help investigators cope
with problems, their resolution is dependent on
strengthening the capacity at all levels of the system.
Fortunately in-country expertise exists in almost all
major aspects of the health research system, which
should greatly facilitate strengthening efforts.22
Building a receptive research environment
Although the capacity to conduct trials was limited, most
researchers agreed that simple design studies could be
carried out. However, local investigators have attempted
few trials. A key problem was the disabling research
environment at the individual level. Clinical trials are a
relatively new phenomenon and are not yet embedded
in the Ethiopian research culture. Therefore, their
implementation can be viewed as a change within this
culture. The Awareness, Desire, Knowledge, Ability and
Reinforcement (ADKAR) model for organisational
change management, suggests that for a change to
happen at an individual level, ADKAR must be
present.24 Trial awareness was limited and investigators
did not have the vision that trials would improve patient
care. Although most participants had the desire to lead
a trial, they reported a general lack of knowledge and
Figure 3 Mechanistic model of the factors influencing clinical trial conduct in Ethiopia.
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competence. For those that had the knowledge, many
still felt unable to lead a trial, or were unwilling because
of minimal motivational reinforcement.
This study, and others,25 26 suggests that increased
learning opportunities and rewarding career paths are
required to increase human resource capacity and retain
skilled personnel. Increasing research components in
taught courses, and providing training and small
research grants for young researchers would increase
awareness, desire and knowledge to conduct research.
In Ethiopia, clinical academic staff have low salaries and
are paid less than public sector physicians.27 This, com-
bined with limited funding, high-teaching burdens, low-
quality facilities and frustrations with bureaucratic and
operational hurdles found in this and another study,27
all serve as strong disincentives to research. Providing
protected time for research and recognising research
within careers would help motivate investigators to
undertake trials through positive reinforcement, but this
alone may not be sufﬁcient without adequate salaries to
offset lost revenue from private practice and consultancy
work.
Several participants expressed their inability to lead
their own trial as a lack of conﬁdence, or phobia and
investigators who had worked on foreign-led studies still
did not feel ready to lead their own trial. Local funding
and material capacity constraints were often cited as the
cause, but many researchers had not applied for inter-
national funding. Expectation of insurmountable bar-
riers and lack of successful role models certainly reduce
conﬁdence. However, it is possible that the intellectual
isolation identiﬁed in this and another study,27 and lack
of a supportive research environment, could reduce ini-
tiative. We also propose that previous regimes that
actively discouraged autonomy, could have left a legacy
that reduced the ability of individuals to act as agents in
change.
Networking
Collaboration was key to the provision of training, knowl-
edge sharing and experience exchange and accessing
technical expertise and infrastructure strengthening.
Better networking within and between local and inter-
national research organisations could facilitate the provi-
sion of these enablers, decrease intellectual isolation
and help develop a National Health Research System.22
Successful local sites are often busy, so exchange place-
ments could be organised to allow more individuals to
get involved. This could potentially increase trial staff
numbers and reduce the impact of task shifting on
clinic work. This may then reverse the negative feedback
loop between insufﬁcient human resources and few
trials. Local research networks could support sustainable
training models if a few experts become trainers of trai-
ners and mentorship programmes linking experts to
junior staff could provide inspirational support and guid-
ance for isolated individuals. The need for administra-
tive support in LMICs is common as many universities
lack established research services.26 28 Cooperation
between departments to form research clusters would
make hiring an administrative assistant affordable and
could help share the cost and burden of purchasing
supplies.
The creation of communities of practice could help to
develop these relationships but proven strategies that
foster their development are not clearly established.29
Networking opportunities such as workshops would be
useful, but ﬁrst, all stakeholders need to be identiﬁed,
and travel, time and cost can be barriers. Also, the infor-
mal nature of partnership formation in this study meant
that less established researchers did not have the con-
tacts or knowledge to ﬁnd partners. One solution could
be to develop a local and international online network-
ing facility, detailing research interests, expertise,
resources and current projects.
Prioritising research systems
Capacity building attached to foreign-led studies typically
focuses on training individuals in speciﬁc skills or pro-
viding one speciﬁc service or resource. While this may
get a particular study completed, in Ethiopia, it does not
appear to provide the package necessary to allow local
investigators to conduct their own trials. This study
demonstrates the diversity of factors inﬂuencing IIT
implementation and shows that focusing on system wide
improvements must be integral to any long-term
research development plan for Ethiopia. For this to
happen, we suggest that research must be prioritised,
not just in terms of resource allocation but also the
value placed on research. However, in a country with
insufﬁcient health workers to provide routine health-
care27 and many other competing priorities, this may be
difﬁcult.
Despite this, such a value change could already be
underway. The Ethiopian Science and Technology
Agency devised strong implementation strategies to
support research in 200630 and built on them in 2012.31
The importance of research and developing research
capacities is now central to the Ministry of Health strat-
egy, and local trial data32 has inﬂuenced policy.33
Recommendations for fostering a research culture in
the New Public Universities have been developed34 and
the Jimma University in South West Ethiopia has been
applauded for pioneering new innovative teaching
methods, valuing research within institutional culture
and integrating it in career progress.27 35 Meanwhile,
The Ethiopian Bioethics Initiative is working hard to
strengthen regulatory procedures and provides a success-
ful example of developing ethical review capacity.
Strengths and limitations
As a formative study, the sample size and range of stake-
holder roles was small, and the ﬁndings may be speciﬁc to
the locations or dependent on contextual factors such as
governance style. Although this limits the breadth of per-
spectives and generalisability of ﬁndings, the study sample
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accessed diverse experiences and used in-depth qualitative
methods to uncover issues in a largely unexplored area,
while giving a compelling voice to local investigators who
are often unheard in this Northern dominated discourse.
The inability to audio record the discussions may have had
some impact on the accuracy of the notes taken. However,
we felt it was more important to ensure open and frank dia-
logue, and the detailed notes were subsequently reviewed
by participants to ensure accurate representation. The
recommendations in this study are congruent with those
proposed by The Ethiopian Ministry of Science and
Technology,30 31 and also agree with much of the current
international literature. This includes the key factors for
enabling a research environment as identiﬁed by The
Health Research System Analysis Initiative of WHO/RPC,21
and recommendations for increasing investigator-initiated
trial conduct by The European Science Foundation.36
Nevertheless it was important to conﬁrm that local investi-
gators in LMICs held similar views as espoused by the
above reports. Our subsequent research on this topic has
been conducted in other settings, including a wider range
of stakeholders in order to overcome these limitations.
CONCLUSION
Developing research capacity to conduct investigator-
initiated trials is multifaceted and likely to require a dif-
ferent strategy to traditional approaches that focus on
individuals or capacity building for speciﬁc studies. An
appreciation of the barriers and enablers at all levels
must be central to development drives. While this study
provides a preliminary step forward in this area, further
work is needed to test these ﬁndings in other settings
and to develop the thorough understanding required to
successfully support these critical studies.
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